LANXESS Aktiengesellschaft

XTRA:LXS Stock Report

Market Cap: €2.0b

LANXESS Valuation

Is LXS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LXS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LXS (€23.39) is trading below our estimate of fair value (€55.51)

Significantly Below Fair Value: LXS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LXS?

Key metric: As LXS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LXS. This is calculated by dividing LXS's market cap by their current revenue.
What is LXS's PS Ratio?
PS Ratio0.3x
Sales€6.32b
Market Cap€2.01b

Price to Sales Ratio vs Peers

How does LXS's PS Ratio compare to its peers?

The above table shows the PS ratio for LXS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.5x
BAS BASF
0.6x4.5%€37.8b
SDF K+S
0.5x0.4%€2.0b
WCH Wacker Chemie
0.6x5.2%€3.6b
TKA thyssenkrupp
0.07x0.3%€2.4b
LXS LANXESS
0.3x2.8%€2.0b

Price-To-Sales vs Peers: LXS is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.5x).

Price to Sales Ratio vs Industry

How does LXS's PS Ratio compare vs other companies in the DE Chemicals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
2HRA H&R GmbH KGaA
0.1x2.7%US$128.40m
NSAK OTI Greentech
0.03xn/aUS$602.27k
B7Y Byotrol
0.04xn/aUS$246.97k
No more companies available in this PS range
LXS 0.3xIndustry Avg. 1.0xNo. of Companies4PS00.40.81.21.62+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: LXS is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Chemicals industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is LXS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LXS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ratio0.3x

Price-To-Sales vs Fair Ratio: LXS is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LXS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€23.39
€29.85
+27.6%
21.6%€42.00€21.00n/a17
Nov ’25€26.51
€30.47
+14.9%
20.2%€42.00€21.00n/a17
Oct ’25€28.10
€29.03
+3.3%
19.9%€42.00€21.00n/a18
Sep ’25€25.53
€28.08
+10.0%
20.0%€42.00€21.00n/a18
Aug ’25€23.58
€28.44
+20.6%
19.2%€42.00€21.00n/a18
Jul ’25€23.08
€28.34
+22.8%
18.5%€42.00€21.00n/a19
Jun ’25€24.80
€28.71
+15.8%
18.0%€42.00€21.00n/a19
May ’25€26.53
€28.15
+6.1%
17.4%€42.00€21.00n/a19
Apr ’25€24.81
€28.12
+13.3%
18.6%€42.00€21.00n/a19
Mar ’25€23.71
€28.67
+20.9%
18.9%€42.00€21.00n/a18
Feb ’25€24.97
€28.67
+14.8%
18.9%€42.00€21.00n/a18
Jan ’25€28.37
€29.08
+2.5%
20.1%€42.00€21.00n/a18
Dec ’24€22.83
€31.82
+39.4%
31.6%€65.00€21.00n/a19
Nov ’24€21.29
€33.29
+56.4%
29.4%€65.00€24.00€26.5119
Oct ’24€24.05
€36.82
+53.1%
29.1%€65.00€25.00€28.1019
Sep ’24€29.66
€38.85
+31.0%
25.9%€65.00€28.00€25.5320
Aug ’24€30.14
€40.77
+35.3%
27.8%€65.00€23.30€23.5820
Jul ’24€27.60
€42.13
+52.7%
26.2%€65.00€23.30€23.0821
Jun ’24€33.60
€49.88
+48.5%
18.9%€69.00€35.00€24.8021
May ’24€36.86
€50.81
+37.8%
18.3%€69.00€35.00€26.5321
Apr ’24€37.83
€50.62
+33.8%
17.9%€69.00€35.00€24.8121
Mar ’24€43.98
€52.29
+18.9%
14.8%€69.00€40.00€23.7121
Feb ’24€45.55
€52.24
+14.7%
14.7%€69.00€40.00€24.9721
Jan ’24€37.70
€50.50
+34.0%
17.3%€69.00€37.50€28.3721
Dec ’23€38.00
€50.93
+34.0%
17.3%€72.00€37.50€22.8321
Nov ’23€34.14
€50.55
+48.1%
21.1%€72.00€31.50€21.2921

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Ecora Resources

UK£159.8m

Operates as a natural resource royalty and streaming company in Australia, North and South America, Europe, and internationally.

HGR

UK£0.77

7D

8.9%

1Y

-29.0%

Central Asia Metals

UK£277.0m

Operates as a base metals producer.

9C3

UK£1.87

7D

0.5%

1Y

-4.1%

Arkema

€5.7b

Manufactures and sells specialty chemicals and advanced materials worldwide.

V1S

€75.20

7D

-2.0%

1Y

-17.2%